# US 2014/0154220 A1 · Methods and Compositions for Improved Tissue Regeneration by Suppression of Interferon-Gamma and Tumor Necrosis Factor-Alpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154220 A1
- Document ID: US20140154220A1
- Status: Published application
- Kind: A1
- Application number: 14/114,070
- Filed: 2012-04-25
- Published: 2014-06-05
- Earliest claimed: 2011-04-25
- Assignees: University of Southern Califonia
- Inventors: Songtao Shi; Yi Liu; Lei Wang
- Web page: https://patentgrep.com/patent/US20140154220A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-α and IFN-γ. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-α, IFN-γ, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-α, IFN-γ, or both.

## Claims

### Claim 1

A complex composition for tissue engineering or a tissue regeneration device, comprising:
at least one bone marrow mesenchymal stem cell; and
an effective amount of a proinflammatory cytokine reducing agent.

### Claim 2 (depends on 1)

The composition or device of claim 1, wherein said proinflammatory cytokine is TNF-α, IFN-γ, or both.

### Claim 3 (depends on 1)

The composition or device of claim 1, wherein said proinflammatory cytokine reducing agent is aspirin.

### Claim 4 (depends on 3)

The composition or device of claim 3, wherein said amount is about 50 μg/ml or more.

### Claim 5 (depends on 1)

The composition or device of claim 1, further comprising a substrate.

### Claim 6 (depends on 5)

The composition or device of claim 5, wherein said substrate is a water-insoluble, non-elastic, porous, pliable material capable of absorbing or adsorbing the BMMSC and the cytokine reducing agent.

### Claim 7 (depends on 6)

The composition or device of claim 6, wherein said substrate is sponge.

### Claim 8 (depends on 1)

A method of BMMSC-mediated tissue engineering, comprising:
applying a complex composition or device according to claim 1 to a site in need of new tissue.

### Claim 9

A method for promoting localized tissue regeneration, comprising:
applying a tissue engineering complex composition to a site in need of tissue regeneration,
wherein said tissue engineering complex composition comprising one or more anti-inflammatory agent(s) to provide a long-term anti-inflammatory environment for seed bone marrow mesenchymal stem cells to grow.

### Claim 10 (depends on 9)

The method of claim 9, wherein said anti-inflammatory agent is an inhibitor or a neutralizer of a cytokine selected from the group consisting of TNF-α, IFN-γ, and both.

### Claim 11 (depends on 10)

The method of claim 10, wherein said anti-inflammatory agent is aspirin.

### Claim 12 (depends on 9)

The method of claim 9, further comprising the step of pre-treating a plurality of bone marrow mesenchymal stem cells with the anti-inflammatory agent(s) before applying the complex to the site.

### Claim 13

A method for forming a tissue engineering complex composition or a tissue regeneration device, comprising:
adding a predetermined amount of bone marrow mesenchymal stem cell and an anti-inflammatory agent to a substrate or a carrier.

### Claim 14 (depends on 13)

The method of claim 13, wherein said anti-inflammatory agent is an inhibitor of TNF-α, IFNy, or both.

### Claim 15

The method of 14, wherein said anti-inflammatory agent is aspirin.

### Claim 16

A method of promoting tissue regeneration at a bone marrow mesenchymal stem cell (BMMSC) implantation site of a subject, comprising:
administering Foxp3+ regulatory T cells to the subject systemically; and
applying a BMMSC-mediated tissue regeneration inducer to the site.

### Claim 17 (depends on 16)

The method of claim 16, wherein said BMMSC-mediated tissue regeneration inducer comprises one or more BMMSC.

### Claim 18 (depends on 17)

The method of claim 17, wherein said tissue regeneration inducer further comprising an anti-inflammatory agent.

### Claim 19 (depends on 18)

The method of claim 18, wherein said anti-inflammatory agent is aspirin.

### Claim 20

A pharmaceutical composition useful for enhancing bone marrow mesenchymal stem cell (BMMSC) mediated tissue regeneration, comprising:
an effective amount of one or more anti-inflammatory agent(s); and
a pharmaceutically acceptable carrier.

### Claim at position 21

21-22. (canceled)
